A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)

NCT05839626 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
32
Enrollment
INDUSTRY
Sponsor class

Stopped Early discontinuation based on sponsor decision not driven by any safety concerns.

Conditions

Interventions

Sponsor

Sanofi